International Lung Cancer Consortium: coordinated association study of 10 potential lung cancer susceptibility variants.

International Agency for Research on Cancer, Lyon 69008, France.
Carcinogenesis (Impact Factor: 5.64). 04/2010; 31(4):625-33. DOI: 10.1093/carcin/bgq001
Source: PubMed

ABSTRACT Analysis of candidate genes in individual studies has had only limited success in identifying particular gene variants that are conclusively associated with lung cancer risk. In the International Lung Cancer Consortium (ILCCO), we conducted a coordinated genotyping study of 10 common variants selected because of their prior evidence of an association with lung cancer. These variants belonged to candidate genes from different cancer-related pathways including inflammation (IL1B), folate metabolism (MTHFR), regulatory function (AKAP9 and CAMKK1), cell adhesion (SEZL6) and apoptosis (FAS, FASL, TP53, TP53BP1 and BAT3).
Genotype data from 15 ILCCO case-control studies were available for a total of 8431 lung cancer cases and 11 072 controls of European descent and Asian ethnic groups. Unconditional logistic regression was used to model the association between each variant and lung cancer risk.
Only the association between a non-synonymous variant of TP53BP1 (rs560191) and lung cancer risk was significant (OR = 0.91, P = 0.002). This association was more striking for squamous cell carcinoma (OR = 0.86, P = 6 x 10(-4)). No heterogeneity by center, ethnicity, smoking status, age group or sex was observed. In order to confirm this association, we included results for this variant from a set of independent studies (9966 cases/11,722 controls) and we reported similar results. When combining all these studies together, we reported an overall OR = 0.93 (0.89-0.97) (P = 0.001). This association was significant only for squamous cell carcinoma [OR = 0.89 (0.85-0.95), P = 1 x 10(-4)].
This study suggests that rs560191 is associated to lung cancer risk and further highlights the value of consortia in replicating or refuting published genetic associations.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The TP53BP1 gene may be involved in the development of cancer through disrupting DNA repair. However, studies investigating the relationship between TP53BP1 Glu353Asp (rs560191) polymorphism and cancer yielded contradictory and inconclusive outcomes. In order to realize these ambiguous findings, a meta-analysis was performed to assess the association between the TP53BP1 Glu353Asp (rs560191) polymorphism and susceptibility to cancer. We conducted a search of all English reports on studies for the association between the TP53BP1 Asp353Glu (rs560191) polymorphism and susceptibility to cancer using Medline, the Cochrane Library, EMbase, Web of Science, Google (scholar), and all Chinese reports were identified manually and on-line using CBMDisc, Chongqing VIP database, and CNKI database. The strict selection criteria and exclusion criteria were determined, and odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of associations. The fixed or random effect model was selected based on the heterogeneity test among studies. Publication bias was estimated using funnel plots and Egger's regression test. A total of seven studies were included in the meta-analysis including 3,213 cases and 3,849 controls. The results indicated that the Glu353Asp (rs560191) polymorphism in TP53BP1 gene had no association with cancer risk for all genetic models. In the subgroup analysis, the results suggested that Glu353Asp polymorphism was not associated with the risk of cancer according to ethnicity, cancer type, genotyping method, adjusted with control or not, HWE and quality score. This meta-analysis suggested that the Glu353Asp (rs560191) polymorphism in TP53BP1 gene was not associated with risk of cancer.
    PLoS ONE 01/2014; 9(3):e90931. · 3.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Interleukin 1, beta (IL1B) plays a key role in mediating acute and chronic inflammation, which is further correlated with lung carcinogenesis. Several polymorphisms on IL1B gene have been identified, and a series of epidemiological studies have examined the association between IL1B polymorphisms and lung cancer risk. However, these findings are inconclusive. To derive a precise estimation of the relationship, a meta-analysis was performed. We summarized 12 eligible publications on three commonly studied IL1B polymorphisms (i.e., -31 T/C, -511 T/C, and +3954 C/T) by searching electronic databases. Combined odds ratio (OR) with 95 % confidence interval (CI) was calculated to assess the strength of association between them. Heterogeneity and publication bias were also assessed. We observed a significant association between IL1B polymorphisms and lung cancer. For -31T/C, the overall OR (95 % CI) of TT/TC versus CC was 1.23 (1.06-1.43). For +3954 C/T, the overall OR (95 % CI) of CC versus TT and CC versus CT/TT were 0.92 (0.86-0.99) and 0.92 (0.86-0.99), respectively. In conclusion, this meta-analysis suggests that the IL1B -31 T/C and +3954 C/T polymorphisms are associated with lung cancer risk. However, larger number of samples and studies with homogeneous lung cancer patients are needed to confirm these findings.
    Tumor Biology 06/2013; · 2.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The study investigated several common SNPs in the tumor protein p53 binding protein 1 gene and tumor protein p53 gene in 640 lung cancer cases and 685 controls in Han Chinese to determine if these single nucleotide polymorphisms (SNPs) were associated with lung cancer risk. Several studies indicated that SNPs in the 53BP1 and TP53 gene are associated with cancer risk. We investigated the association between common SNP variants in the 53BP1, TP53 gene and lung cancer risk. We used real-time PCR method to investigate the genotypic frequencies of rs2602141, rs560191 and rs689647 in 53BP1 and rs1042522 in TP53 in 640 cases of lung cancer and 685 controls. SNPs rs2602141, rs560191 and rs689647 in 53BP1 were in complete linkage disequilibrium in Han Chinese. The frequencies of the G/G, G/T and T/T genotypes of rs2602141 were 17.5, 50.3 and 32.2% in cases and 21.0, 49.3 and 29.6% in controls, respectively and distributions were not significantly different (p = 0.236). The rs2602141 T/T genotype increased NSCLC risk (OR = 1.56, 95% CI = 1.10-2.21). The genotype distribution frequency of rs1042522 does not demonstrate significant differences between cases and control group. 53BP1 and TP53 gene interactions were not associated with lung cancer risk.
    Archives of medical research 12/2013; · 1.88 Impact Factor

Full-text (2 Sources)

Available from
May 15, 2014